← All trials
NCT04912518
N/AInterventional
Trials without FDA-defined phases, including trials of devices or behavioral interventions.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 27, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Jun 3, 2021
- Last posted
- Nov 24, 2021
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harbin Medical UniversityLead sponsor
- Anhui Medical UniversityOverall official - principal investigator
- Harbin Medical UniversityOverall official - principal investigator
- Harbin Medical UniversityReponsible party - principal investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Tianjin Medical UniversityOverall official - principal investigator
- LanZhou UniversityOverall official - principal investigator
- Shaanxi Provincial People's HospitalOverall official - principal investigator
- Yangtze River Pharmaceutical Group Co., Ltd.Collaborator
- Henan Provincal People's HospitalOverall official - principal investigator
- Shanxi cardiovascular hospitalOverall official - principal investigator
- Mudanjiang cardiovascular hospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.